Immediate ICU Management for Severe Sepsis with Multi-Organ Failure
This patient requires immediate aggressive resuscitation following Surviving Sepsis Campaign guidelines, with urgent initiation of broad-spectrum antibiotics within 1 hour, aggressive crystalloid fluid resuscitation (minimum 30 mL/kg), norepinephrine as first-line vasopressor to maintain MAP ≥65 mmHg, and consideration for urgent renal replacement therapy given the severe metabolic acidosis (pH likely <7.15 based on CO2 20, anion gap 22, lactate 5.5) combined with profound uremia (BUN 76, Cr 8.65, eGFR 6). 1
Critical Initial Actions (First Hour)
1. Immediate Resuscitation Bundle
- Obtain blood cultures immediately, then start broad-spectrum antibiotics within 1 hour of sepsis recognition—this is a grade 1B recommendation and directly impacts mortality 2, 1
- Aggressive fluid resuscitation: Administer minimum 30 mL/kg crystalloid bolus (approximately 2-3 liters for average adult) over first 3 hours, with more rapid administration likely needed given the severe hypoperfusion (lactate 5.5, elevated troponin 254 suggesting cardiac involvement) 2
- Initiate norepinephrine as first-choice vasopressor to maintain MAP ≥65 mmHg (grade 1B)—do not wait for fluid resuscitation to complete if patient remains hypotensive 1
2. Respiratory Management
Given hypoxemia (PaO2 60, O2 sat 89%), this patient likely requires mechanical ventilation with lung-protective strategies:
- Target tidal volume 6 mL/kg predicted body weight (grade 1A) 1
- Maintain plateau pressure ≤30 cm H2O (grade 1B) 1
- Apply adequate PEEP to prevent atelectasis (grade 1B) 1
- If PaO2/FiO2 ratio ≤100 mmHg, consider prone positioning in facilities with experience (grade 2B) 1, 2
- Elevate head of bed 30-45 degrees to prevent aspiration (grade 1B) 1
Renal Replacement Therapy Decision
This patient has clear indications for urgent RRT:
The 2016 Surviving Sepsis guidelines suggest against using RRT solely for creatinine elevation or oliguria without definitive indications 1. However, this patient has multiple absolute indications:
- Severe metabolic acidosis (CO2 20, anion gap 22, lactate 5.5) with pH likely <7.15
- Severe uremia (BUN 76, Cr 8.65) with potential for uremic complications
- Hyperkalemia risk (not provided but likely given eGFR 6)
- Fluid overload management will be critical with ongoing resuscitation
Initiate either continuous RRT (CRRT) or intermittent hemodialysis—both are equivalent for mortality (grade 2B), but CRRT is preferred for hemodynamically unstable patients to facilitate fluid balance management 1, 3. Target CRRT dose of 20-25 mL/kg/hr of effluent generation 3.
Important Caveat on Bicarbonate Therapy
Do NOT administer sodium bicarbonate for metabolic acidosis unless pH <7.15 (weak recommendation, moderate quality evidence) 1, 3. The guidelines specifically recommend against bicarbonate therapy to improve hemodynamics or reduce vasopressor requirements at pH ≥7.15. If pH is <7.15, bicarbonate may be considered, but RRT is the preferred approach for severe acidosis in this context.
Additional Critical Management
Blood Product Administration
- Hemoglobin 12.2 g/dL is adequate—transfuse RBCs only if Hgb drops <7.0 g/dL, targeting 7.0-9.0 g/dL (grade 1B), unless active myocardial ischemia given elevated troponin 1
- Platelet count 89 is borderline—prophylactic transfusion recommended if <10,000/mm³ without bleeding, or <20,000/mm³ with bleeding risk. For active bleeding or invasive procedures, maintain platelets ≥50,000/mm³ (grade 2D) 1, 2, 1
- Do NOT transfuse FFP (INR 1.2 is acceptable) unless active bleeding or planned invasive procedure (grade 2D) 1
Glucose Management
Glucose 247 mg/dL requires insulin therapy:
- Target blood glucose ≤180 mg/dL (NOT <110 mg/dL, which increases hypoglycemia risk) (grade 1A) 2
- Monitor glucose every 1-2 hours until stable, then every 4 hours 1
- Use arterial blood for point-of-care testing if arterial line present 1
Corticosteroids
Consider hydrocortisone 200 mg/day ONLY if vasopressor-dependent shock persists despite adequate fluid resuscitation (grade 2C) 1. Do NOT use ACTH stimulation test to guide therapy (grade 2B) 1. Taper when vasopressors no longer required (grade 2D) 1.
Thromboprophylaxis and Stress Ulcer Prophylaxis
Initiate pharmacologic VTE prophylaxis with LMWH (preferred over UFH, grade 1B/strong recommendation) 1, 3
- Critical exception: With severe renal dysfunction (eGFR 6), use UFH instead of LMWH, or use dalteparin which has low renal metabolism (grade 1A) 1
- With thrombocytopenia (PLT 89), continue pharmacologic prophylaxis unless active bleeding or platelet count drops further; add mechanical prophylaxis (sequential compression devices) 1
Initiate stress ulcer prophylaxis with PPI or H2-blocker given bleeding risk factors (mechanical ventilation, coagulopathy, thrombocytopenia) (grade 1B/strong recommendation) 1
Monitoring Priorities
- Lactate clearance: Repeat lactate every 2-4 hours—persistent elevation despite resuscitation indicates ongoing tissue hypoperfusion and predicts poor outcomes 2
- Troponin 254 suggests sepsis-induced myocardial dysfunction—consider dobutamine if signs of low cardiac output persist despite adequate MAP and fluid resuscitation (grade 1C) 2, 1
- Arterial line placement recommended for all patients requiring vasopressors (weak recommendation) 1
- Central venous access for vasopressor administration and potential ScvO2 monitoring
Common Pitfalls to Avoid
- Delaying antibiotics to obtain cultures—obtain cultures quickly but never delay antibiotics beyond 1 hour 2, 1, 2
- Inadequate initial fluid resuscitation—30 mL/kg is the minimum; many patients require substantially more 2
- Using dopamine as first-line vasopressor—norepinephrine is superior (grade 1B) 2, 1
- Avoiding RRT in severe metabolic acidosis—this patient has definitive indications beyond just elevated creatinine 1, 3
- Overtransfusing RBCs—restrictive strategy (Hgb 7-9 g/dL) is appropriate unless active ischemia 1
- Using LMWH for VTE prophylaxis with eGFR 6—switch to UFH or dalteparin 1
- Tight glucose control targeting <110 mg/dL—increases hypoglycemia without benefit; target <180 mg/dL 2, 1